Recurrent or Metastatic Head and Neck cancer - Pipeline Insight, 2024

Recurrent or Metastatic Head and Neck cancer - Pipeline Insight, 2024

DelveInsight’s, Recurrent or Metastatic Head and Neck cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Recurrent or Metastatic Head and Neck cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Recurrent or Metastatic Head and Neck cancer Understanding

Recurrent or Metastatic Head and Neck cancer: Overview

Traditionally patients with recurrence of head and neck cancer (HNC) are considered to have poor prognosis. As a result the majority of these patients are usually treated with palliative intent or receive best supportive care. Head and neck cancers are the sixth most common cancer worldwide, and arise from the upper aerodigestive mucosa, salivary glands, and skin. Despite differences in histology and biology across cancer types, most treatment protocols are extrapolated from head and neck squamous cell carcinoma (HNSCC the most common histology. Recurrent and metastatic disease is usually incurable. There are significant gaps in knowledge. Unlike other cancer types, there are no predictive biomarkers, and no new targeted therapies have been approved for HNSCC other than cetuximab in 2006.

""Recurrent or Metastatic Head and Neck cancer - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Recurrent or Metastatic Head and Neck cancer pipeline landscape is provided which includes the disease overview and Recurrent or Metastatic Head and Neck cancer treatment guidelines. The assessment part of the report embraces, in depth Recurrent or Metastatic Head and Neck cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Recurrent or Metastatic Head and Neck cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Recurrent or Metastatic Head and Neck cancer. The therapies under development are focused on novel approaches to treat/improve Recurrent or Metastatic Head and Neck cancer.

Recurrent or Metastatic Head and Neck cancer Emerging Drugs

Xevinapant: Merck

Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care. Merck gains exclusive global development and commercialization rights; Debiopharm to receive € 188 million upfront and up to € 710 million in regulatory and commercial milestones, as well as royalty payments

SI B001: Sichuan Baili Pharmaceutical

SI B001 is a bispecific antibody designed with the proprietary platform technology developed by Baili and SystImmune. It can bind to EGFR and HER3, and simultaneously inhibits the ligand induced EGFR×EGFR homodimers, the formation of EGFR×HER3 heterodimers and the activation of its downstreamsignal pathway. SI-B001 can also induce endocytosis of EGFR and HER3, anddown-regulate the levels of EGFR and HER3 tumor cells. In preclinical studies, SI-B001 has demonstrated superior tumor killing activities. SI-B001 Phase I trials have shown good safety and preliminary efficacy.

Further product details are provided in the report……..

Recurrent or Metastatic Head and Neck cancer: Therapeutic Assessment

This segment of the report provides insights about the Recurrent or Metastatic Head and Neck cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Recurrent or Metastatic Head and Neck cancer

There are approx. 40+ key companies which are developing the therapies Recurrent or Metastatic Head and Neck cancer. The companies which have their Recurrent or Metastatic Head and Neck cancer drug candidates in the most advanced stage, i.e phase III include Eisai Co

• Phases

DelveInsight’s report covers around 40+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Recurrent or Metastatic Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Recurrent or Metastatic Head and Neck cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Recurrent or Metastatic Head and Neck cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Recurrent or Metastatic Head and Neck cancer drugs.

Recurrent or Metastatic Head and Neck cancer Report Insights

• Recurrent or Metastatic Head and Neck cancer Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Recurrent or Metastatic Head and Neck cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Recurrent or Metastatic Head and Neck cancer drugs?
• How many Recurrent or Metastatic Head and Neck cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Recurrent or Metastatic Head and Neck cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Recurrent or Metastatic Head and Neck cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Recurrent or Metastatic Head and Neck cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eisai Co Ltd
• Sinocelltech
• Merck
• Nanobiotix
• Sichuan Baili Pharmaceutical
• Adlai Nortye Biopharma
• BioNTech
• PDS Biotechnology
• Shanghai Miracogen
• Incyte Corporation
• Checkmate Pharmaceuticals
• NATCO Pharma
• Agenus
• Jiangsu Hengrui Medicine
• Cue Biopharma
• AbbVie

Key Products

• Lenvatinib
• Finotonlimab
• Xevinapant
• Hafnium oxide
• SI B001
• Buparlisib
• BNT 113
• PDS0101
• MRG003
• Retifanlimab
• Vidutolimod
• NRC-2694-A
• Ragifilimab
• Retlirafusp alfa
• CUE 101
• Revdofilimab